Schwerpunkt Tyrosinkinaseinhibitor-Wechselwirkungen

Effekte von Nahrung und Magen-pH-Modulation unter TKI-Therapie

This is a preview of subscription content, access via your institution.



  1. 1.

    Lipp HP. Wechselwirkungen mit oralen Tumortherapeutika. MMP. 2020;43(9):340-51

  2. 2.

    Koch KM et al. The Value of Label Recommendations: How to Dose Lapatinib. J Clin Oncol. 2007;25(33):5331-2

  3. 3.

    Messori A et al. Effect of Food on Lapatinib Pharmacokinetics. J Clin Oncol. 2007;25(33):5332-3

  4. 4.

    Yokota H et al. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer. Clin Lung Cancer. 2017;18(6):e433-e439

  5. 5.

    Numico G et al. Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use. Crit Rev Oncol Hematol. 2017;111:144-51

  6. 6.

    Reiner R, Stark H. PPI - wie war das noch? Deutsche ApothekerZeitung. 2019;159(30):2780-4

  7. 7.

    Tang W et al. Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. Clin Pharmacol Drug Dev. 2017;6(5):517-23

  8. 8.

    Hussaarts KGAM et al. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347

  9. 9.

    Storr M. Aktuelle und zukünftige Therapien der gastroösophagealen Refluxerkrankung. MMP 2011;34(12):446-54

  10. 10.

    Yu G et al. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye. Lancet Oncol. 2014;15(11):e469-70

  11. 11.

    Van Leeuwen RWF et al. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(12):1309-14

  12. 12.

    Yago MR et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014;16(6):1358-65

  13. 13.

    Ha VH et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract. 2015;21(3):194-200

  14. 14.

    Cheng V et al. Concomitant use of capecitabine and proton pump inhibitors - Is it safe? J Oncol Pharm Pract. 2019;25(7):1705-11

  15. 15.

    Alicja Puszkiel et al. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. Clin Pharmacokinet. 2019;58(4):451-67

  16. 16.

    Mächler S et al. Vor, zum oder nach dem Essen? Deutsche ApothekerZeitung. 2016;156(22):2110-7

  17. 17.

    Pajares B et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol. 2012;14(2):94-101

  18. 18.

    Chi KN et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015;55(12):1406-14

  19. 19.

    Dartsch D. Mit Einnahmehinweisen gegen Interaktionen. So wird die orale Krebstherapie sicherer. DAZ 2020;160(7):582-9

  20. 20.

    Smollich M, Podlogar J. Wechselwirkungen zwischen Arzneimitteln und Lebensmitteln. 2020: Wissenschaftliche Verlagsgesellschaft, Stuttgart

  21. 21.

    Ge J et al. Interaction of green tea polyphenol EGCG with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl). 2011;89(6):595-602

  22. 22.

    Massoud M et al. Procarbazine in haematology: an old drug with a new life? Eur J Cancer. 2004;40(13):1924-7

  23. 23.

    Clippe C et al. Lethal toxicity of capecitabine due to abusive folic acid prescription? Clin Oncol (R Coll Radiol). 2003;15(5):299-300

  24. 24.

    Verheijen RB et al. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clin Pharmacol Ther. 2017;102(5):765-76

  25. 25.

    Haas B et al. Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues. Regul Toxicol Pharmacol. 2016;77:25-34

Download references

Author information



Corresponding author

Correspondence to Prof. Dr. rer. nat. Hans-Peter Lipp.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lipp, HP. Effekte von Nahrung und Magen-pH-Modulation unter TKI-Therapie. InFo Hämatol Onkol 24, 10–17 (2021).

Download citation